Melody Parker

A Novel Prognostic Metric Resolves the MYCN enigma in Silico and Points to a Biosynthetic Regulatory Shift Driven by MYCN Amplification in Neuroblastoma Neuroblastoma (NB) is the most common extra-cranial solid tumour in children. Although MYCN amplification is typically indicative of a poor prognosis, the expression level of MYCN has a non-monotonic ...

🔹 Favourable outcomes in MYCN-amplified tumours require very high biosynthesis and ATM signalling — rarely achievable biologically.

Read here: biorxiv.org/content/10.1...
#neuroblastoma #modelling #cancerresearch

We propose:
🔹 The p53/MYCN ratio is a superior prognostic metric to MYCN alone in neuroblastoma.
🔹 MYCN drives biogenesis, but amplification or co-mutations trigger a shift that lowers p53/MYCN → worse outcomes.
⬇️

5 years ago, my MSc project with @insigneoinstitute.bsky.social modelled the MYCN–MDM2–ARF–p53 network in neuroblastoma. That work has evolved into a full study!

The preprint by Matteo et al. explores the MYCN enigma — why MYCN amplification predicts poor prognosis, but overexpression alone doesn’t

Delighted to share that the revised version of this work on the genetic basis of infertility is now out in @naturegenet.bsky.social ! Give it a read and let us know what you think - rdcu.be/ehEgG 🧬💻